论文部分内容阅读
目的:观察奥扎格雷在治疗非ST段抬高的急性冠脉综合征的疗效。方法:回顾性分析我院2009年6月-2011年6月间收治的符合非ST段抬高的急性冠脉综合征100例患者临床资料,将患者随机分为三组,阿司匹林组、阿司匹林+奥扎格雷组与阿司匹林+氯吡格雷+奥扎格雷组。结果:治疗后二联组、三联组临床疗效均明显优于阿司匹林组(P<0.05)。血液动力学参数均较治疗前明显降低(P<0.05),且以上指标明显低于阿司匹林组。结论:奥扎格雷钠治疗非ST段抬高急性冠脉综合征可降低心绞痛和急性心肌梗死发生率。
Objective: To observe the efficacy of ozagrel in the treatment of non-ST segment elevation acute coronary syndrome. Methods: The clinical data of 100 patients with non-ST-segment elevation acute coronary syndrome who were treated in our hospital from June 2009 to June 2011 were retrospectively analyzed. The patients were randomly divided into three groups: aspirin group, aspirin + Ozagrel group and aspirin + clopidogrel + ozagrel group. Results: The curative effect of two groups and three groups were better than aspirin group after treatment (P <0.05). Hemodynamic parameters were significantly lower than before treatment (P <0.05), and the above indicators were significantly lower than aspirin group. Conclusion: Ozagrel sodium in non-ST segment elevation acute coronary syndromes can reduce the incidence of angina pectoris and acute myocardial infarction.